Chicago, IL3 Active Studies

Recurrent Pregnancy Loss Clinical Trials in Chicago, IL

Find 3 actively recruiting recurrent pregnancy loss clinical trials in Chicago, IL. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
766
Enrolling

Recruiting Recurrent Pregnancy Loss Studies in Chicago

About Recurrent Pregnancy Loss Clinical Trials in Chicago

Recurrent pregnancy loss is defined as two or more failed pregnancies and affects about 1-2% of couples trying to conceive. Causes include chromosomal abnormalities, uterine anomalies, and immune factors. Treatment depends on the underlying cause and may include hormonal support, surgery, or immunotherapy.

There are currently 3 recurrent pregnancy loss clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 766 participants. Research is being sponsored by Yale University, Crinetics Pharmaceuticals Inc., University of Illinois at Chicago. Clinical trial participation is free and participants receive study-related medical care at no cost.

Recurrent Pregnancy Loss Clinical Trials in Chicago — FAQ

Are there recurrent pregnancy loss clinical trials in Chicago?

Yes, there are 3 recurrent pregnancy loss clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What recurrent pregnancy loss treatments are being tested?

The 3 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for recurrent pregnancy loss.

Data updated July 13, 2026 from ClinicalTrials.gov